Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The update aims to help the public better protect themselves and understand their risk.
New studies offer evidence that an unexpected virus plays a role—but it needs a helper.
Antibody levels decrease substantially within three months after a booster, according to new clinical trial data.
The engineered protein vaccine was highly effective in a clinical trial but faced a long delay for authorization.
Two drugs widely used to treat certain autoimmune diseases substantially improved clinical status and reduced deaths.
After a long wait, the FDA authorizes Pfizer and Moderna vaccines for children as young as 6 months old.
The virus can be transmitted via respiratory droplets at close range, but it does not spread through the air over longer distances.
Vaccines designed to produce a strong T cell response may help protect against current and future SARS-CoV-2 variants.
Approximately 1 in 3 Americans 65 and older who completed their initial vaccination round still have not received a first booster shot.
Nearly 200 cases of pediatric hepatitis have now been reported in more than a dozen countries and several states.
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.
Novel therapies, improved technologies and a better understanding of the immune system could yield broad dividends.
Immunocompromised people ages 12 and older are also eligible for an additional shot.
Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.
Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.